Information from Merck about EMEND® – Availability of a New NDC
- Amanda Bridges
- July 10, 2017
- News
Merck has received FDA approval for a new formulation of EMEND for injection that has a lower concentration of edetate disodium (EDTA), an inactive ingredient. This new formulation (5.4 mg EDTA, NDC 0006-3061-00) will replace the existing formulation (18.8 mg EDTA, NDC 0006-3941-32). The purpose of this formulation change is to support ongoing regulatory activities for EMEND. Please ensure that your systems and processes are updated with the new NDC.
Before prescribing EMEND® (fosaprepitant dimeglumine) for injection, please read the accompanying Prescribing Information (5.4 mg EDTA formulation). The Patient Information also is available.
